An antibody, a pharmaceutical composition, and a method
WO2021075478A1
Method for quantifying amino group-containing compound protected by protecting group having fmoc skeleton
WO2021070885A1
Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition
WO2021065568A1
Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
WO2021039945A1
Cross-species anti-latent tgf-beta 1 antibodies and methods of use
WO2021010326A1
Anti-mutation type fgfr3 antibody and use therefor
WO2021006328A1
Claudin-6 binding molecules and uses thereof
WO2020262576A1
Antigen binding molecules that bind pdgf-b and pdgf-d and uses thereof
WO2020250915A1
Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
WO2020246617A1
Information processing system, information processing method, program, and method for producing antigen-binding molecule or protein.
WO2020246567A1
Protease substrate, and polypeptide including protease cleavage sequence
WO2020246563A1
Antibody cleavage site-binding molecule
WO2020230834A1
An antigen-binding molecule, a pharmaceutical composition, and a method
WO2020218465A1
Method for diagnosing endometriosis, disease state monitoring method, and kit
WO2020213724A1
Chimeric receptor recognizing modification site of antibody
WO2020213706A1
Antibodies and compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
WO2020209318A1
Method for purifying fc region-modified antibody
JP2020121811A
Package of PTP sheet
WO2020204054A1
Anti-hla-dq2.5 antibody
WO2020204055A1
Method of introducing target-specific foreign gene
